Experts
Headquartered in Auckland, New Zealand, Aroa Biosurgery is a soft-tissue regeneration company committed to unlocking regenerative healing for everybody through its patented AROA ECM™ complex wound and tissue reconstruction products.
The company was founded in 2008 by Veterinarian Surgeon Dr Brian Ward, who discovered that a tissue scaffold called the extra cellular matrix (ECM) found in the forestomach of sheep has a similar structure to human tissue and contains over 150 proteins known to be important in the healing process.
Listed on the ASX since 2020, Aroa Biosurgery has established USA operations, regulatory approval in over 50 countries and employs over 270 people in New Zealand and North America.
Over 6 million AROA products have been used globally in a range of procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELA Bio, Inc. www.aroabio.com
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
Cast your eyes over these 15 weird and wonderful biotech stocks we found on the ASX
Experts
ScoPo’s Powerplays: Who else needs help remembering the good times of ASX health stocks?
Health & Biotech
Check Up: Money managers are still bullish on Healthcare; here’s what they said
News
ASX Small Cap Lunch Wrap: Who applied for their forklift drivers test today?
Health & Biotech
Mesoblast has long been the one poster child for stem cell therapy. Now Cynata and other ASX stocks have emerged
News
Closing Bell: ASX drops again, hit by APRA lending restrictions and NZ rate hike
Director Trades
Directors’ Trades: Resources has been off the boil, but these directors just took a punt on their companies
Health & Biotech
Check up: Rhinomed (ASX:RNO) soars with NSW COVID contract, and genetic testing fails to impress
Health & Biotech
ASX health stocks: EMV’s brain scanner is completed and ready for testing, stock price jumps 16pc
Experts
These ASX stocks were the pick of the bunch at the Pinnacle Investment Summit
Health & Biotech
ScoPo’s Powerplays: Smaller capped health stocks are still in ‘no man’s land’, but Neuren jumps 18pc this week
Health & Biotech
Dr Boreham’s Crucible: Who’s winning and losing in the life sciences IPO Olympiad?
Health & Biotech
ScoPo’s Powerplays: Solid earnings for health stocks all round, but price action stays with larger caps
Health & Biotech
New breakthrough in stem cells research paves the way for ASX regenerative medicine stocks
News
Last Orders: ASX returns from Easter break with a gain
News
With America vaccinating 2 million a day, here are 3 ASX medtechs that will benefit as lockdowns are lifted
Experts